Literature DB >> 29681620

Recontacting or not recontacting? A survey of current practices in clinical genetics centres in Europe.

Fabio Sirchia1, Daniele Carrieri2, Sandi Dheensa3, Caroline Benjamin4,5, Hülya Kayserili6, Christophe Cordier7, Carla G van El8, Peter D Turnpenny9, Bela Melegh10, Álvaro Mendes11, Tanya F Halbersma-Konings12, Irene M van Langen12, Anneke M Lucassen3,13, Angus J Clarke14, Francesca Forzano15, Susan E Kelly16.   

Abstract

Advances in genomic medicine are improving diagnosis and treatment of some health conditions, and the question of whether former patients should be recontacted is therefore timely. The issue of recontacting is becoming more important with increased integration of genomics in 'mainstream' medicine. Empirical evidence is needed to advance the discussion over whether and how recontacting should be implemented. We administered a web-based survey to genetic services in European countries to collect information about existing infrastructures and practices relevant to recontacting patients. The majority of the centres stated they had recontacted patients to update them about new significant information; however, there were no standardised practices or systems in place. There was also a multiplicity of understandings of the term 'recontacting', which respondents conflated with routine follow-up programmes, or even with post-test counselling. Participants thought that recontacting systems should be implemented to provide the best service to the patients and families. Nevertheless, many barriers to implementation were mentioned. These included: lack of resources and infrastructure, concerns about potential negative psychological consequences of recontacting, unclear operational definitions of recontacting, policies that prevent healthcare professionals from recontacting, and difficulties in locating patients after their last contact. These barriers are also intensified by the highly variable development (and establishment) of the specialties of medical genetics and genetic counselling across different European countries. Future recommendations about recontacting need to consider these barriers. It is also important to reach an 'operational definition' that can be useful in different countries.

Entities:  

Mesh:

Year:  2018        PMID: 29681620      PMCID: PMC6018700          DOI: 10.1038/s41431-018-0131-5

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  21 in total

1.  Duty to recontact: a legal harbinger?

Authors:  B M Knoppers
Journal:  Am J Med Genet       Date:  2001-11-01

2.  Genetic registers in clinical practice: a survey of UK clinical genetics.

Authors:  J C Dean; D R Fitzpatrick; P A Farndon; H Kingstn; D Cusine
Journal:  J Med Genet       Date:  2000-08       Impact factor: 6.318

3.  The coming explosion in genetic testing--is there a duty to recontact?

Authors:  Reed E Pyeritz
Journal:  N Engl J Med       Date:  2011-10-13       Impact factor: 91.245

4.  The inverse care law.

Authors:  J T Hart
Journal:  Lancet       Date:  1971-02-27       Impact factor: 79.321

5.  The duty to recontact: attitudes of genetics service providers.

Authors:  J L Fitzpatrick; C Hahn; T Costa; M J Huggins
Journal:  Am J Hum Genet       Date:  1999-03       Impact factor: 11.025

6.  Impact of a genetic diagnosis of a mitochondrial disorder 5-17 years after the death of an affected child.

Authors:  A C Sexton; M Sahhar; D R Thorburn; S A Metcalfe
Journal:  J Genet Couns       Date:  2008-02-12       Impact factor: 2.537

7.  Changing interpretations, stable genes: responsibilities of patients, professionals, and policy makers in the clinical interpretation of complex genetic information.

Authors:  Brian H Shirts; Lisa S Parker
Journal:  Genet Med       Date:  2008-11       Impact factor: 8.822

8.  Duty to re-contact.

Authors:  K Hirschhorn; L D Fleisher; L Godmilow; R R Howell; R R Lebel; E R McCabe; M J McGinniss; A Milunsky; M Z Pelias; R E Pyeritz; E Sujansky; B H Thompson; R E Zinberg
Journal:  Genet Med       Date:  1999 May-Jun       Impact factor: 8.822

9.  Recontact in clinical practice: a survey of clinical genetics services in the United Kingdom.

Authors:  Daniele Carrieri; Anneke M Lucassen; Angus J Clarke; Sandi Dheensa; Shane Doheny; Peter D Turnpenny; Susan E Kelly
Journal:  Genet Med       Date:  2016-02-18       Impact factor: 8.822

10.  Recontacting in clinical practice: an investigation of the views of healthcare professionals and clinical scientists in the United Kingdom.

Authors:  Daniele Carrieri; Sandi Dheensa; Shane Doheny; Angus J Clarke; Peter D Turnpenny; Anneke M Lucassen; Susan E Kelly
Journal:  Eur J Hum Genet       Date:  2017-01-04       Impact factor: 4.246

View more
  11 in total

1.  Reply to Bombard and Mighton.

Authors:  Daniele Carrieri; Heidi C Howard; Angus J Clarke; Vigdis Stefansdottir; Martina C Cornel; Carla G van El; Francesca Forzano
Journal:  Eur J Hum Genet       Date:  2019-01-18       Impact factor: 4.246

2.  Recontacting clinical genetics patients with reclassified results: equity and policy challenges.

Authors:  Yvonne Bombard; Chloe Mighton
Journal:  Eur J Hum Genet       Date:  2019-04       Impact factor: 4.246

3.  The Responsibility to Recontact Research Participants after Reinterpretation of Genetic and Genomic Research Results.

Authors:  Yvonne Bombard; Kyle B Brothers; Sara Fitzgerald-Butt; Nanibaa' A Garrison; Leila Jamal; Cynthia A James; Gail P Jarvik; Jennifer B McCormick; Tanya N Nelson; Kelly E Ormond; Heidi L Rehm; Julie Richer; Emmanuelle Souzeau; Jason L Vassy; Jennifer K Wagner; Howard P Levy
Journal:  Am J Hum Genet       Date:  2019-04-04       Impact factor: 11.025

4.  Opinions and experiences of recontacting patients: a survey of Australasian genetic health professionals.

Authors:  Bhavya Bhupen Vora; Helen Mountain; Cassandra Nichols; Lyn Schofield
Journal:  J Community Genet       Date:  2022-01-11

5.  Recontacting registry participants with genetic updates through GenomeConnect, the ClinGen patient registry.

Authors:  Juliann M Savatt; Danielle R Azzariti; David H Ledbetter; Emily Palen; Heidi L Rehm; Erin Rooney Riggs; Christa Lese Martin
Journal:  Genet Med       Date:  2021-05-18       Impact factor: 8.822

6.  Increased diagnostic yield by reanalysis of data from a hearing loss gene panel.

Authors:  Yu Sun; Jiale Xiang; Yidong Liu; Sen Chen; Jintao Yu; Jiguang Peng; Zijing Liu; Lisha Chen; Jun Sun; Yun Yang; Yaping Yang; Yulin Zhou; Zhiyu Peng
Journal:  BMC Med Genomics       Date:  2019-05-28       Impact factor: 3.063

7.  Recontacting patients in clinical genetics services: recommendations of the European Society of Human Genetics.

Authors:  Daniele Carrieri; Heidi C Howard; Caroline Benjamin; Angus J Clarke; Sandi Dheensa; Shane Doheny; Naomi Hawkins; Tanya F Halbersma-Konings; Leigh Jackson; Hülya Kayserili; Susan E Kelly; Anneke M Lucassen; Álvaro Mendes; Emmanuelle Rial-Sebbag; Vigdís Stefánsdóttir; Peter D Turnpenny; Carla G van El; Irene M van Langen; Martina C Cornel; Francesca Forzano
Journal:  Eur J Hum Genet       Date:  2018-10-11       Impact factor: 4.246

8.  Share and protect our health data: an evidence based approach to rare disease patients' perspectives on data sharing and data protection - quantitative survey and recommendations.

Authors:  Sandra Courbier; Rebecca Dimond; Virginie Bros-Facer
Journal:  Orphanet J Rare Dis       Date:  2019-07-12       Impact factor: 4.123

9.  Reinterpretation, reclassification, and its downstream effects: challenges for clinical laboratory geneticists.

Authors:  Julia El Mecky; Lennart Johansson; Mirjam Plantinga; Angela Fenwick; Anneke Lucassen; Trijnie Dijkhuizen; Annemieke van der Hout; Kate Lyle; Irene van Langen
Journal:  BMC Med Genomics       Date:  2019-11-29       Impact factor: 3.063

10.  Assessment of genetic referrals and outcomes for women with triple negative breast cancer in regional cancer centres in Australia.

Authors:  Lucie G Hallenstein; Carol Sorensen; Lorraine Hodgson; Shelly Wen; Justin Westhuyzen; Carmen Hansen; Andrew T J Last; Julan V Amalaseelan; Shehnarz Salindera; William Ross; Allan D Spigelman; Thomas P Shakespeare; Noel J Aherne
Journal:  Hered Cancer Clin Pract       Date:  2021-02-26       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.